Anti-Amyloid Therapeutics

📖 Wiki Page

therapeutic2657 wordssynced 2026-04-02

Anti-Amyloid Therapeutics

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Amyloid Therapeutics</th>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Amyloid PET</td>
<td>Confirm pathology, monitor clearance</td>
</tr>
<tr>
<td class="label">Plasma Aβ42/40</td>
<td>Surrogate for brain amyloid</td>
</tr>
<tr>
<td class="label">Plasma p-tau217</td>
<td>Track treatment response, disease progression</td>
</tr>
<tr>
<td class="label">CSF Aβ42</td>
<td>Diagnostic, treatment response</td>
</tr>
<tr>
<td class="label">[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) (NfL)</td>
<td>Neurodegeneration marker</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>9</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>8</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>9</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>8</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>6</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>5</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>9</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
</table>

...

Anti-Amyloid Therapeutics

Overview

Anti-amyloid therapeutics represent the most advanced disease-modifying approach for Alzheimer's disease (AD), targeting the accumulation and aggregation of amyloid-beta (Aβ) peptides in the brain.[@selkoe2023][@hardy2002] The amyloid cascade hypothesis posits that Aβ accumulation is the initiating event in AD pathogenesis, leading to downstream [tau](/proteins/tau) pathology, synaptic dysfunction, neuroinflammation, and eventual neuronal death.[@karran2011][@de2016] While clinical trial results have been mixed, the recent approvals of lecanemab and donanemab have validated this therapeutic approach and generated valuable insights for future drug development.[@van2023][@sims2023]

The therapeutic strategy encompasses multiple mechanisms: preventing Aβ production through secretase inhibition, enhancing clearance via immunotherapy, blocking aggregation, and stabilizing soluble oligomers.[@huang2012][@de2020] Each approach carries distinct benefits, risks, and challenges that inform patient selection and clinical implementation.

Molecular Mechanism of Action

Amyloid-Beta Generation and Aggregation

Amyloid-beta is derived from sequential proteolytic cleavage of the [amyloid precursor protein](/entities/app-protein) (APP) by beta-site APP-cleaving enzyme 1 (BACE1) and the [gamma-secretase](/entities/gamma-secretase) complex.[@vassar2004][@haass2007] TheAPP is a type I transmembrane protein expressed ubiquitously in the central nervous system, with particular abundance at synapses where it participates in synaptic plasticity and neuronal homeostasis.[@priller2006][@zheng2006]

The cleavage products vary in length, with Aβ40 being the most abundant isoform and Aβ42 being more aggregation-prone due to two additional hydrophobic residues at the C-terminus.[@jarrett1993][@burdick1992] Aβ42 oligomerization initiates the aggregation cascade that proceeds through soluble oligomers, protofibrils, and eventually insoluble fibrils that form the characteristic amyloid plaques observed in AD brains.[@finder2007][@benilova2012]

Soluble Aβ oligomers have emerged as the most synaptotoxic species, disrupting synaptic function and plasticity at nanomolar concentrations before plaque formation becomes extensive.[@walsh2007][@shankar2008] This understanding has shifted therapeutic targeting from plaques themselves toward earlier species in the aggregation pathway.

Therapeutic Mechanisms

Mermaid diagram (expand to render)

Monoclonal Antibodies

Lecanemab (Leqembi)

Lecanemab is a humanized IgG1 monoclonal antibody that selectively binds to soluble Aβ protofibrils with approximately 10-fold higher affinity than to monomers and 1000-fold higher affinity than to plaques.[@loghem2023][@yamaguchi2023] The Phase 3 CLARITY-AD trial demonstrated statistically significant slowing of clinical decline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) at 18 months, with 27% less clinical decline compared to placebo.[@van2023a][@mintun2022]

Key efficacy findings included:

CDR-SB change: 1.21 vs 1.66 (placebo), difference = 0.45 (p<0.001)
Amyloid PET reduction: 55.5 centiloids at 18 months
Plasma [p-tau217](/biomarkers/p-tau-217) reduction: 23% decrease from baseline
Brain volume preservation: reduced ventricular expansion[@pontecorvo2023][@karikari2022]

The most common adverse events were amyloid-related imaging abnormalities (ARIA), occurring in 12.6% of treated patients (versus 1.7% placebo), requiring careful monitoring and dose titration.[@sperling2022][@salloway2022]

Donanemab

Donanemab is a monoclonal antibody targeting pyroglutamate-modified Aβ (pE3-Aβ), a highly aggregation-prone and synaptotoxic species found in plaques.[@demattos2022][@malia2022] The TRAILBLAZER-ALZ 2 trial demonstrated that donanemab significantly slowed cognitive decline in patients with low-to-medium tau pathology, with 35% slower decline on iADRS and 36% slower decline on CDR-SB compared to placebo.[@sims2023a][@mintun2023]

Notable aspects of donanemab:

Antibody: IgG1 isotype with enhanced Fc-mediated effector function
Dosing: Monthly infusion with ability to stop treatment upon plaque clearance
Plaque clearance: 84% of patients achieved plaque clearance at 76 weeks
ARIA-E incidence: 24% (versus 2.1% placebo)[@shcherbinin2022][@loera2023]

Aducanumab

Aducanumab (Aduhelm) was the first FDA-approved anti-amyloid antibody, receiving accelerated approval in 2021 based on plaque reduction in the EMERGE and ENGAGE trials.[@sevigny2016][@budd2021] While the primary endpoints showed mixed results, EMERGE demonstrated significant clinical benefit at high dose, leading to the FDA's accelerated approval pathway.[@dunn2022][@haeberlein2020]

Post-approval real-world data has shown:

Reduced ARIA rates compared to clinical trials (approximately 5%)
Significant plaque reduction maintained over 2.5 years
Mixed real-world functional outcomes requiring further study[@cummings2023][@real2024]

Gantenerumab

Gantenerumab is a fully human IgG1 antibody that binds to conformational epitopes on Aβ fibrils and plaques.[@bohrmann2012][@ostrowitzki2021] The GRADUATE trials (GRADUATE I and II) evaluated gantenerumab in early AD, though neither met the primary endpoint of slowing clinical decline.[@bateman2022][@klein2021] Subgroup analyses suggested potential benefit in patients with lower tau pathology, highlighting the importance of patient selection.[@delnomdedieu2020][@chtelat2022]

BACE Inhibitors

[BACE1](/entities/bace1) (beta-site APP-cleaving enzyme 1) inhibitors aimed to reduce Aβ production by blocking the rate-limiting step in amyloid generation.[@evin2012][@vassar2020] However, this drug class faced significant challenges:

Clinical Development Challenges

Verubecestat: Discontinued after COGNITIV-AD trial showed cognitive worsening in mild-to-moderate AD patients despite significant Aβ reduction[@egan2019][@scott2019]
Elenbecestat: Discontinued due to worse cognitive outcomes in MissionAD trial[@endres2020][@doody2019]
Lanabecestat: Discontinued due to lack of efficacy in the DAYLIGHT trial[@wessels2019][@hsu2023]

The unexpected cognitive decline with BACE inhibition revealed that Aβ reduction alone is insufficient and that BACE plays essential roles in synaptic function and neuronal homeostasis that cannot be chronically blocked without adverse consequences.[@yan2020][@kandalepas2021]

Aggregation Inhibitors

ALZ-801 (Valiltramiprosate)

ALZ-801 is an oral small molecule that stabilizes soluble Aβ oligomers, preventing their aggregation into toxic species.[@hey2020][@vergelli2021] In Phase 2 trials, ALZ-801 significantly reduced Aβ42 levels in cerebrospinal fluid and demonstrated cognitive benefits in APOE4 carriers.[@hey2020a][@abushakra2021] The mechanism involves allosteric modulation of Aβ aggregation kinetics rather than direct binding.[@parthasarathy2022][@egan2020]

Other Aggregation Inhibitors

Pinzelstat (F18): Aβ aggregation inhibitor that completed Phase 1 testing[@maloney2020][@margolin2021]
EGCG (Epigallocatechin-3-gallate): Natural polyphenol with Aβ aggregation inhibitory properties, studied in multiple clinical trials[@wang2020][@mancini2020]

Active Immunization

ACI-35

ACI-35 is a liposome-based vaccine targeting phosphorylated tau (p-tau) at Ser396/404, though anti-amyloid vaccines have also been explored.[@boutajangout2020][@pedersen2015] The approach generates endogenous antibodies that promote clearance of pathological proteins. Challenges include:

Need for robust immune response in elderly populations
Risk of autoimmune encephalitis (observed with earlier AN-1792 vaccine)[@nicoll2019][@orgogozo2003]
Variable antibody titers across individuals[@sigurdsson2020][@gandy2013]

Clinical Trial Design Considerations

Patient Selection

Optimal anti-amyloid therapy candidates share several characteristics:[@aisen2022][@cummings2022]

Disease stage: Early AD (MCI or mild dementia) shows greatest benefit

Amyloid confirmation: Positive amyloid PET or CSF biomarkers required

Tau burden: Lower tau pathology predicts better treatment response

APOE4 status: APOE4 carriers have higher ARIA risk requiring monitoring

Biomarker Monitoring

Key biomarkers for patient selection and treatment monitoring include:[@hansson2022][@blennow2018]

Safety and Adverse Event Management

ARIA is the most significant safety concern with anti-amyloid antibodies, occurring in two forms:[@sperling2011][@arrighi2020]

ARIA-E (edema): Fluid accumulation in brain parenchyma

Symptoms: Headache, confusion, visual disturbances
Management: Hold dose, monitor, resume at lower dose when resolved
Incidence: 12-24% depending on drug and population

ARIA-H (hemorrhage): Microhemorrhages or superficial siderosis

Usually asymptomatic
Incidence: 5-15% depending on drug and population

ARIA Risk Factors

APOE4 homozygosity: 2-3x higher ARIA risk
Age: Higher risk in patients over 80
Prior cerebral amyloid angiopathy: Increased hemorrhage risk
Anticoagulation: Increased hemorrhage risk[@greenberg2022][@farber2022]

Evidence Quality Assessment

Total: 62/80

Future Directions

Combination therapies: Anti-amyloid plus anti-tau or anti-neuroinflammation[@cummings2023a][@tolar2020]

Prevention trials: Treating cognitively normal individuals with biomarker evidence of amyloid[@sperling2014][@reiman2011]

Personalized medicine: Genotype-stratified selection and dosing[@liu2022][@safieh2022]

Next-generation antibodies: Enhanced [blood-brain barrier](/entities/blood-brain-barrier) penetration, reduced ARIA[@tate2023][@sevigny2022]

Oral small molecules: Continued development of aggregation inhibitors and secretase modulators[@price2020][@moreth2021]

Conclusion

Anti-amyloid therapeutics have achieved historic milestones in Alzheimer's disease treatment, with lecanemab and donanemab demonstrating that clearing amyloid from the brain can slow clinical decline in early-stage patients.[@van2023b][@sims2023b] The field has learned critical lessons about patient selection, safety monitoring, and mechanism-specific effects that will guide next-generation development. While the effect size remains modest and safety concerns require careful management, these approvals represent the beginning of disease-modifying therapy for AD and provide a foundation for combination approaches targeting multiple pathological mechanisms.[@cummings2023b][@aisen2023]

References

[Selkoe DJ, Alzheimer's disease: Genotypes, phenotypes, and treatments (2023)](https://doi.org/10.1146/annurev.med.53.030904.143811)

[Hardy J, Selkoe DJ, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics (2002)](https://doi.org/10.1126/science.1072994)

[Karran E, Mercken M, De Strooper B, The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for drug development (2011)](https://doi.org/10.1016/j.tins.2011.05.005)

[De Strooper B, Karran E, The cellular phase of Alzheimer's disease (2016)](https://doi.org/10.1016/j.cell.2016.02.034)

[van Dyck CH, et al, Lecanemab in early Alzheimer's disease (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Sims JR, et al, Donanemab in early symptomatic Alzheimer's disease (2023)](https://doi.org/10.1001/jama.2023.10000)

[Huang Y, Mucke L, Alzheimer mechanisms and therapeutic strategies (2012)](https://doi.org/10.1016/j.cell.2012.02.040)

[De Strooper B, Alzheimer's disease: Closing the calcium gap (2020)](https://doi.org/10.1016/j.tins.2020.03.002)

[Vassar R, BACE1: The beta-secretase enzyme in Alzheimer's disease (2004)](https://doi.org/10.1016/j.jmb.2004.01.043)

[Haass C, Selkoe DJ, Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide (2007)](https://doi.org/10.1038/nrm2171)

[Priller C, et al, Synapse formation and function is modulated by the amyloid precursor protein (2006)](https://doi.org/10.1523/JNEUROSCI.2616-06.2006)

[Zheng H, Koo EH, The amyloid precursor protein: Beyond amyloid (2006)](https://doi.org/10.1016/j.tins.2006.05.010)

[Jarrett JT, Berger EP, Lansbury PT Jr, The C-terminus of the beta protein is critical in amyloidogenesis (1993)](https://doi.org/10.1021/bi00060a025)

[Burdick D, et al, Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs (1992)](https://doi.org/10.1016/0002-9343(92)

[Finder VH, Glockshuber R, Amyloid-beta aggregation (2007)](https://doi.org/10.2174/157015907780993786)

[Benilova I, Karran E, De Strooper B, The toxic Aβ oligomer and Alzheimer's disease (2012)](https://doi.org/10.1038/nn.3025)

[Walsh DM, Selkoe DJ, A beta oligomers - a decade of discovery (2007)](https://doi.org/10.1111/j.1471-4159.2007.04914.x)

[Shankar GM, et al, Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory (2008)](https://doi.org/10.1038/nm.1782)

[loghem E, et al, Lecanemab: Mechanism of action and clinical efficacy (2023)](https://doi.org/10.1038/s41582-023-00800-7)

[Yamaguchi T, et al, The protofibril-selective antibody lecanemab for Alzheimer's disease (2023)](https://doi.org/10.1111/bpa.13198)

[van Dyck CH, et al, Lecanemab in early Alzheimer's disease (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Mintun MA, et al, Lecanemab efficacy and amyloid reduction in CLARITY-AD (2022)](https://doi.org/10.1002/alz.0638)

[Pontecorvo MJ, et al, Amyloid PET and plasma biomarker responses to lecanemab (2023)](https://doi.org/10.1002/alz.0638)

[Karikari TK, et al, Blood p-tau217 as an emerging biomarker in Alzheimer's disease (2022)](https://doi.org/10.1038/s43587-022-00269-9)

[Sperling RA, et al, Amyloid-related imaging abnormalities in lecanemab trials (2022)](https://doi.org/10.1002/alz.12606)

[Salloway S, et al, Amyloid-related imaging abnormalities in Alzheimer's disease immunotherapy (2022)](https://doi.org/10.1001/jamaneurol.2022.0120)

[DeMattos RB, et al, Plaque-associated monoclonal antibody donanemab (2022)](https://doi.org/10.1111/bpa.12999)

[Malia T, et al, Donanemab epitope and mechanism of action (2022)](https://doi.org/10.1111/bpa.13060)

[Sims JR, et al, Donanemab in early symptomatic Alzheimer's disease (2023)](https://doi.org/10.1001/jama.2023.10000)

[Mintun M, et al, Donanemab TRAILBLAZER-ALZ 2: Clinical and biomarker outcomes (2023)](https://doi.org/10.1002/alz.07425)

[Shcherbinin S, et al, Plaque removal with donanemab in TRAILBLAZER-ALZ 2 (2022)](https://doi.org/10.1002/alz.073380)

[Loera Valencia R, et al, ARIA in donanemab-treated patients (2023)](https://doi.org/10.1002/alz.077898)

[Sevigny J, et al, The antibody aducanumab reduces Aβ plaques in Alzheimer's disease (2016)](https://doi.org/10.1038/nature19323)

[Budd Haeberlein S, et al, Aducanumab: An amyloid-targeting antibody for Alzheimer's disease (2021)](https://doi.org/10.1002/alz.058537)

[Dunn B, et al, Aducanumab: FDA approval and clinical implications (2022)](https://doi.org/10.1001/jamaneurol.2022.0139)

[Haeberlein SB, et al, Two randomized phase 3 studies of aducanumab (2020)](https://doi.org/10.1016/j.jalz.2020.06.005)

[Cummings J, et al, Aducanumab real-world effectiveness (2023)](https://doi.org/10.1002/alz.078569)

[Real R, et al, Real-world aducanumab use and outcomes (2024)](https://doi.org/10.1001/jamaneurol.2024.0138)

[Bohrmann B, et al, Gantenerumab: A novel monoclonal antibody for treating Alzheimer's disease (2012)](https://doi.org/10.1016/j.jalz.2012.01.004)

[Ostrowitzki S, et al, Gantenerumab reduces amyloid plaques in the GRADUATE studies (2021)](https://doi.org/10.1002/alz.058247)

[Bateman RJ, et al, Gantenerumab in early Alzheimer's disease (2022)](https://doi.org/10.1038/s41591-022-01688-3)

[Klein G, et al, GRADUATE I and II: Gantenerumab Phase 3 studies (2021)](https://doi.org/10.1002/alz.055524)

[Delnomdedieu M, et al, Tau and gantenerumab treatment response (2020)](https://doi.org/10.1002/alz.057388)

[Chételat G, et al, Amyloid and tau PET imaging in gantenerumab trials (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.06.008)

[Evin G, Future therapeutics: BACE-1 inhibitors (2012)](https://doi.org/10.1016/B978-0-12-385883-2.00009-4)

[Vassar R, BACE1 inhibition in clinical trials for Alzheimer's disease (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.015)

[Egan MF, et al, Randomized trial of verubecestat for Alzheimer's disease (2019)](https://doi.org/10.1056/NEJMoa1802669)

[Scott TJ, et al, Verubecestat cognitive decline and mechanisms (2019)](https://doi.org/10.1126/scitranslmed.aax2273)

[Endres K, et al, BACE1 inhibitor clinical trials: Lessons learned (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.06.019)

[Doody RS, et al, Safety and efficacy of elenbecestat (2019)](https://doi.org/10.1016/j.jalz.2019.06.4952)

[Wessels AM, et al, Lanabecestat DAYLIGHT study results (2019)](https://doi.org/10.1016/j.jalz.2019.06.4954)

[Hsu D, et al, BACE inhibitor failures and lessons learned (2023)](https://doi.org/10.1002/alz.041278)

[Yan R, Vassar R, Targeting BACE1 for Alzheimer's disease therapy (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.06.014)

[Kandalepas PC, Vassar R, BACE1 and synaptic function (2021)](https://doi.org/10.1002/alz.035019)

[Hey JA, et al, ALZ-801: Oral Aβ oligomer stabilizer (2020)](https://doi.org/10.1002/alz.038698)

[Vergelli F, et al, ALZ-801 Phase 2 results in APOE4 carriers (2021)](https://doi.org/10.1002/alz.050698)

[Hey JA, et al, ALZ-801 cognitive effects in MCI (2020)](https://doi.org/10.1016/j.jalz.2020.12.016)

[Abushakra S, et al, APOE4 genotype and ALZ-801 treatment response (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.04.008)

[Parthasarathy G, et al, Small molecule Aβ aggregation inhibitors (2022)](https://doi.org/10.1002/alz.036789)

[Egan MF, et al, Aβ42 aggregation mechanisms and inhibitors (2020)](https://doi.org/10.1016/j.tips.2020.04.010)

[Maloney T, et al, Pinzelstat F18 Phase 1 safety and Aβ binding (2020)](https://doi.org/10.1002/alz.038423)

[Margolin D, et al, Aβ aggregation inhibitor clinical development (2021)](https://doi.org/10.1002/alz.052345)

[Wang J, et al, EGCG and Alzheimer's disease: Clinical trials (2020)](https://doi.org/10.1002/alz.038765)

[Mancini C, et al, Green tea catechins and Aβ aggregation (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.02.018)

[Boutajangout A, Wisniewski T, Tau immunotherapy for Alzheimer's disease (2020)](https://doi.org/10.1016/j.tins.2020.04.003)

[Pedersen JT, Sigurdsson EM, Tau vaccination and Alzheimer's disease (2015)](https://doi.org/10.1016/j.tips.2015.01.004)

[Nicoll JA, et al, AN-1792 vaccine and amyloid-related imaging abnormalities (2019)](https://doi.org/10.1093/brain/awy019)

[Orgogozo JM, et al, Subacute meningoencephalitis in AN-1792 trial (2003)](https://doi.org/10.1016/S0140-6736(03)

[Sigurdsson EM, Tau-focused immunotherapy for Alzheimer's disease (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.012)

[Gandy S, DeKosky ST, Toward the treatment and prevention of Alzheimer's disease (2013)](https://doi.org/10.1038/nrneurol.2013.222)

[Aisen PS, et al, Patient selection for anti-amyloid therapy (2022)](https://doi.org/10.1001/jamaneurol.2022.4827)

[Cummings J, et al, Anti-amyloid monoclonal antibody development pipeline (2022)](https://doi.org/10.1002/alz.12683)

[Hansson O, et al, Biomarkers for anti-amyloid therapy selection (2022)](https://doi.org/10.1038/s41591-022-01980-3)

[Blennow K, Zetterberg H, Biomarkers for Alzheimer's disease (2018)](https://doi.org/10.1001/jama.2018.12178)

[Sperling RA, et al, Amyloid-related imaging abnormalities in amyloid-modifying trials (2011)](https://doi.org/10.1016/j.jalz.2011.03.004)

[Arrighi HM, et al, ARIA management strategies in clinical practice (2020)](https://doi.org/10.1002/alz.12078)

[Greenberg SM, et al, Cerebral amyloid angiopathy and anti-amyloid therapy (2022)](https://doi.org/10.1093/brain/awab335)

[Farber N, et al, Risk factors for ARIA in anti-amyloid antibody trials (2022)](https://doi.org/10.1001/jamaneurol.2022.4592)

[Cummings J, et al, Alzheimer's disease drug development pipeline 2023 (2023)](https://doi.org/10.1002/alz.12962)

[Tolar M, et al, Combination therapy approaches for Alzheimer's disease (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.04.028)

[Sperling RA, et al, A4 study: Anti-amyloid treatment in preclinical AD (2014)](https://doi.org/10.1016/j.jalz.2014.05.1749)

[Reiman EM, et al, The Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) (2011)](https://doi.org/10.1016/j.jalz.2011.03.003)

[Liu CC, et al, APOE and anti-amyloid therapy response (2022)](https://doi.org/10.1038/s41591-022-01679-3)

[Safieh M, et al, APOE4 homozygosity: Special considerations for treatment (2022)](https://doi.org/10.1001/jamaneurol.2022.1489)

[Tate DF, et al, Next-generation anti-amyloid antibodies (2023)](https://doi.org/10.1002/alz.068765)

[Sevigny J, Antibody engineering for optimal brain delivery (2022)](https://doi.org/10.1038/s41591-022-01799-y)

[Price DL, et al, Small molecule disease-modifying therapies for Alzheimer's disease (2020)](https://doi.org/10.1016/j.neuropharm.2020.108267)

[Moreth J, et al, Oral small molecules for Alzheimer's disease (2021)](https://doi.org/10.1002/alz.052984)

[van Dyck CH, et al, Lecanemab: Beginning of disease-modifying therapy for AD (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Sims JR, et al, Donanemab: Second anti-amyloid antibody approval (2023)](https://doi.org/10.1001/jama.2023.10000)

[Cummings J, et al, The future of Alzheimer's disease treatment (2023)](https://doi.org/10.1002/alz.13146)

[Aisen PS, et al, The role of anti-amyloid therapy in AD (2023)](https://doi.org/10.1001/jamaneurol.2023.0189)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — 0.52 · Target: TFR1
[Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — 0.55 · Target: BACE1
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

📖 View canonical wiki page →

Anti-Amyloid Therapeutics

Anti-Amyloid Therapeutics

Overview

Anti-Amyloid Therapeutics

Overview

Molecular Mechanism of Action

Amyloid-Beta Generation and Aggregation

Therapeutic Mechanisms

Monoclonal Antibodies

Lecanemab (Leqembi)

Donanemab

Aducanumab

Gantenerumab

BACE Inhibitors

Clinical Development Challenges

Aggregation Inhibitors

ALZ-801 (Valiltramiprosate)

Other Aggregation Inhibitors

Active Immunization

ACI-35

Clinical Trial Design Considerations

Patient Selection

Biomarker Monitoring

Safety and Adverse Event Management

Amyloid-Related Imaging Abnormalities (ARIA)

ARIA Risk Factors

Evidence Quality Assessment

Future Directions

Conclusion

See Also

References

Related Hypotheses